Selective enhacement of mesocortical dopaminergic transmission by noradrenergic drugs: Therapeutic opportunities in schizophrenia

International Journal of Neuropsychopharmacology

Volumn 14, Issue 1, 2011, Pages 53-68

  Masana, Mercè ^a,b   Bortolozzi, Analía ^a,b   Artigas, Francesc ^a,b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

Antipsychotics; dopamine; noradrenaline; nucleus accumbens; prefrontal cortex

Indexed keywords

2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; ALPHA 2 ADRENERGIC RECEPTOR; CLOZAPINE; DOPAMINE; DOPAMINE AUTORECEPTOR; HALOPERIDOL; NOMIFENSINE; REBOXETINE; VANOXERINE; 2-METHOXYIDAZOXAN; ADRENERGIC RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; DRUG DERIVATIVE; IDAZOXAN; MORPHOLINE DERIVATIVE; NEUROLEPTIC AGENT; NORADRENALIN; NORADRENALIN TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; ELECTROSTIMULATION; HISTOPATHOLOGY; LOCUS CERULEUS; MALE; MESOCORTICAL DOPAMINERGIC TRANSMISSION; MICRODIALYSIS; NEGATIVE FEEDBACK; NEGATIVE SYNDROME; NONHUMAN; NORADRENERGIC SYSTEM; NUCLEUS ACCUMBENS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN TARGETING; RAT; SCHIZOPHRENIA; VENTRAL TEGMENTUM; VENTROMEDIAL PREFRONTAL CORTEX; ANIMAL; CHEMICALLY INDUCED DISORDER; COGNITION; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; SYNAPTIC TRANSMISSION; WISTAR RAT;

ADRENERGIC AGENTS; ANIMALS; ANTIPSYCHOTIC AGENTS; COGNITION; DOPAMINE; DOPAMINE AGENTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; ELECTRIC STIMULATION; HALOPERIDOL; IDAZOXAN; MALE; MICRODIALYSIS; MOLECULAR TARGETED THERAPY; MORPHOLINES; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; RATS; RATS, WISTAR; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION; VENTRAL TEGMENTAL AREA;

EID: 79952763594     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145710000908     Document Type: Article

References (94)

1. Abercrombie ED, Zigmond MJ (1989). Partial injury to central noradrenergic neurons: reduction of tissue norepinephrine content is greater than reduction of extracellular norepinephrine measured by microdialysis. Journal of Neuroscience 9, 4062-4067. (Pubitemid 20004900)
2. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, et al. (2000). Increased baseline occupancy of d2 receptors by dopamine in schizophrenia. Proceedings of the National Academy of Sciences USA 97, 8104-8109. (Pubitemid 30460780)
3. Adell A, Artigas F (1991). Differential effects of clomipramine given locally or systemically on extracellular 5-hydroxytryptamine in raphe nuclei and frontal cortex. an in vivo brain microdialysis study. Naunyn-Schmiedeberg's Archives of Pharmacology 343, 237-244.
4. Adell A, Sarna GS, Hutson PH, Curzon G (1989). An in vivo dialysis and behavioural study of the release of 5-HT by p-chloroamphetamine in reserpine-treated rats. British Journal of Pharmacology 97, 206-212. (Pubitemid 19113965)
5. Akil M, Pierri JN, Whitehead RE, Edgar CL, et al. (1999). Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. American Journal of Psychiatry 156, 1580-1589. (Pubitemid 29459991)
6. Arnsten AF, Li BM (2005). Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biological Psychiatry 57, 1377-1384. (Pubitemid 40798558)
7. Artaloytia JF, Arango C, Lahti A, Sanz J, et al. (2006). Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. American Journal of Psychiatry 163, 488-493. (Pubitemid 44469392)
8. Artigas F, Romero L, de Montigny C, Blier P (1996). Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends in Neuroscience 19, 378-383. (Pubitemid 26270513)
9. Ashby CR, Wang RY (1996). Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse 24, 349-394. (Pubitemid 26418687)
10. Auclair A, Cotecchia S, Glowinski J, Tassin JP (2002). D-amphetamine fails to increase extracellular dopamine levels in mice lacking alpha 1b-adrenergic receptors: relationship between functional and nonfunctional dopamine release. Journal of Neuroscience 22, 9150-9154. (Pubitemid 35356155)
11. Auclair A, Drouin C, Cotecchia S, Glowinski J, et al. (2004). 5-HT2A and alpha1b-adrenergic receptors entirely mediate dopamine release, locomotor response and behavioural sensitization to opiates and psychostimulants. European Journal of Neuroscience 20, 3073-3084. (Pubitemid 40007302)
12. Bel N, Artigas F (1992). Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. European Journal of Pharmacology 229, 101-103.
13. Berridge CW, Stratford TL, Foote SL, Kelley AE (1997). Distribution of dopamine beta-hydroxylase-like immunoreactive fibers within the shell subregion of the nucleus accumbens. Synapse 27, 230-241. (Pubitemid 27430672)
14. Bortolozzi A, Artigas F (2003). Control of 5-hydroxytryptamine release in the dorsal raphe nucleus by the noradrenergic system in rat brain. Role of alpha-adrenoceptors. Neuropsychopharmacology 28, 421-434.
15. Bortolozzi A, Diaz-Mataix L, Scorza MC, Celada P, et al. (2005). The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. Journal of Neurochemistry 95, 1597-1607. (Pubitemid 41804057)
16. 2A receptors. International Journal of Neuropsychopharmacology. Published online: 17 February 2010. doi:10.1017/S146114571000009X.
17. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, et al. (2002). Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/ hyperactivity disorder. Neuropsychopharmacology 27, 699-711. (Pubitemid 35335888)
18. Carboni E, Silvagni A, Vacca C, Di Chiara G (2006). Cumulative effect of norepinephrine and dopamine carrier blockade on extracellular dopamine increase in the nucleus accumbens shell, bed nucleus of stria terminalis and prefrontal cortex. Journal of Neurochemistry 96, 473-481.
19. Carboni E, Tanda GL, Frau R, Di Chiara G (1990). Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. Journal of Neurochemistry 55, 1067-1070.
20. Carlsson A (1978). Antipsychotic drugs, neurotransmitters, and schizophrenia. American Journal of Psychiatry 135, 165-173.
21. Castner SA, Williams GV, Goldman-Rakic PS (2000). Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 287, 2020-2022. (Pubitemid 30158679)
22. Creese I, Burt DR, Snyder SH (1976). Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192, 481-483.
23. Dailly E, Chenu F, Petit-Demouliere B, Bourin M (2006). Specificity and efficacy of noradrenaline, serotonin depletion in discrete brain areas of Swiss mice by neurotoxins. Journal of Neuroscience Methods 150, 111-115. (Pubitemid 41770805)
24. Darracq L, Blanc G, Glowinski J, Tassin JP (1998). Importance of the noradrenaline-dopamine coupling in the locomotor activating effects of D-amphetamine. Journal of Neuroscience 18, 2729-2739. (Pubitemid 28141818)
25. Delfs JM, Zhu Y, Druhan JP, Aston-Jones GS (1998). Origin of noradrenergic afferents to the shell subregion of the nucleus accumbens: anterograde and retrograde tract-tracing studies in the rat. Brain Research 806, 127-140. (Pubitemid 29010488)
26. Devoto P, Flore G, Pani L, Gessa GL (2001). Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex. Molecular Psychiatry 6, 657-664. (Pubitemid 33020584)
27. Devoto P, Flore G, Pira L, Longu G, et al. (2004). Alpha2-adrenoceptor mediated co-release of dopamine and noradrenaline from noradrenergic neurons in the cerebral cortex. Journal of Neurochemistry 88, 1003-1009. (Pubitemid 38199322)
28. Devoto P, Flore G, Saba P, Fa M, et al. (2005). Stimulation of the locus coeruleus elicits noradrenaline and dopamine release in the medial prefrontal and parietal cortex. Journal of Neurochemistry 92, 368-374. (Pubitemid 40194027)
29. Devoto P, Flore G (2006). On the origin of cortical dopamine: is it a co-transmitter in noradrenergic neurons? Current Neuropharmacology 4, 115-125.
30. Devoto P, Flore G, Saba P, Castelli MP, et al. (2008). 6-Hydroxydopamine lesion in the ventral tegmental area fails to reduce extracellular dopamine in the cerebral cortex. Journal of Neuroscience Research 86, 1647-1658. (Pubitemid 351642458)
31. Di Chiara G, Tanda GL, Frau R, Carboni E (1992). Heterologous monoamine reuptake: lack of transmitter specificity of neuron-specific carriers. Neurochemistry International 20, 231S-235S.
32. Diaz-Mataix L, Scorza MC, Bortolozzi A, Toth M, et al. (2005). Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. Journal of Neuroscience 25, 10831-10843. (Pubitemid 41692613)
33. Floresco SB, Magyar O (2006). Mesocortical dopamine modulation of executive functions: beyond working memory. Psychopharmacology (Berlin) 188, 567-585. (Pubitemid 46758962)
34. Florin-Lechner SM, Druhan JP, Aston-JonesG,Valentino RJ (1996). Enhanced norepinephrine release in prefrontal cortex with burst stimulation of the locus coeruleus. Brain Research 742, 89-97. (Pubitemid 27016011)
35. Fritschy JM, Grzanna R (1989). Immunohistochemical analysis of the neurotoxic effects of DSP-4 identifies two populations of noradrenergic axon terminals. Neuroscience 30, 181-197. (Pubitemid 19159807)
36. Goldman-Rakic PS, Muly III EC, Williams GV (2000). D(1) receptors in prefrontal cells and circuits. Brain Research Reviews 31, 295-301.
37. Grandoso L, Pineda J, Ugedo L (2004). Comparative study of the effects of desipramine and reboxetine on locus coeruleus neurons in rat brain slices. Neuropharmacology 46, 815-823. (Pubitemid 38368914)
38. Grenhoff J, Svensson TH (1993). Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area. European Journal of Pharmacology 233, 79-84. (Pubitemid 23091746)
39. Gresch PJ, Sved AF, Zigmond MJ, Finlay JM (1995). Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex. Journal of Neurochemistry 65, 111-116.
40. Grzanna R, Berger U, Fritschy JM, Geffard M (1989). Acute action of DSP-4 on central norepinephrine axons: biochemical and immunohistochemical evidence for differential effects. Journal of Histochemistry and Cytochemistry 37, 1435-1442. (Pubitemid 19212762)
41. Gu H, Wall SC, Rudnick G (1994). Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. Journal of Biological Chemistry 269, 7124-7130. (Pubitemid 24217896)
42. Harden DG, King D, Finlay JM, Grace AA (1998). Depletion of dopamine in the prefrontal cortex decreases the basal electrophysiological activity of mesolimbic dopamine neurons. Brain Research 794, 96-102. (Pubitemid 28298870)
43. Hertel P, Fagerquist MV, Svensson TH (1999b). Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science 286, 105-107. (Pubitemid 29484485)
44. Hertel P, Nomikos GG, Svensson TH (1999a). Idazoxan preferentially increases dopamine output in the rat medial prefrontal cortex at the nerve terminal level. European Journal of Pharmacology 371, 153-158. (Pubitemid 29216997)
45. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, et al. (2001). 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. Journal of Neurochemistry 76, 1521-1531. (Pubitemid 32198256)
46. Invernizzi RW, Garattini S (2004). Role of presynaptic alpha2-adrenoceptors in antidepressant action: recent findings from microdialysis studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry 28, 819-827. (Pubitemid 39195273)
47. Jonsson G, Hallman H, Ponzio F, Ross S (1981). DSP4 (N-(2-chloroethyl)-N- ethyl-2-bromobenzylamine) - a useful denervation tool for central and peripheral noradrenaline neurons. European Journal of Pharmacology 72, 173-188. (Pubitemid 11072495)
48. Kane J, Honigfeld G, Singer J, Meltzer H (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 45, 789-796.
49. Kawahara H, Kawahara Y, Westerink BH (2001). The noradrenaline-dopamine interaction in the rat medial prefrontal cortex studied by multi-probe microdialysis. European Journal of Pharmacology 418, 177-186. (Pubitemid 32441577)
50. Keefe RS, Young CA, Rock SL, Purdon SE, et al. (2006). One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophrenia Research 81, 1-15.
51. King D, Finlay JM (1995). Effects of selective dopamine depletion in medial prefrontal cortex on basal and evoked extracellular dopamine in neostriatum. Brain Research 685, 117-128.
52. Kuroki T, Meltzer HY, Ichikawa J (1999). Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. Journal of Pharmacology and Experimental Therapeutics 288, 774-781. (Pubitemid 29119694)
53. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, et al. (1996). Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings of the National Academy of Sciences USA 93, 9235-9240.
54. Letchworth SR, Smith HR, Porrino LJ, Bennett BA, et al. (2000). Characterization of a tropane radioligand, [(3)H]2beta-propanoyl-3beta-(4-tolyl) tropane ([(3)H]PTT), for dopamine transport sites in rat brain. Journal of Pharmacology and Experimental Therapeutics 293, 686-696. (Pubitemid 30244124)
55. Leucht S, Corves C, Arbter D, Engel RR, et al. (2009). Second-generation vs. first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373, 31-41.
56. Lewis DA, Lieberman JA (2000). Catching up on schizophrenia: natural history and neurobiology. Neuron 28, 325-334.
57. Li XM, Perry KW, Wong DT, Bymaster FP (1998). Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology (Berlin) 136, 153-161. (Pubitemid 28137955)
58. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209-1223. (Pubitemid 41345943)
59. Linner L, Endersz H, Ohman D, Bengtsson F, et al. (2001). Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex. Journal of Pharmacology and Experimental Therapeutics 297, 540-546. (Pubitemid 32377983)
60. Marshall JF, O'Dell SJ, Navarrete R, Rosenstein AJ (1990). Dopamine high-affinity transport site topography in rat brain: major differences between dorsal and ventral striatum. Neuroscience 37, 11-21. (Pubitemid 20262226)
61. Mateo Y, Pineda J, Meana JJ (1998). Somatodendritic alpha2-adrenoceptors in the locus coeruleus are involved in the in vivo modulation of cortical noradrenaline release by the antidepressant desipramine. Journal of Neurochemistry 71, 790-798. (Pubitemid 28480428)
62. Mazei MS, Pluto CP, Kirkbride B, Pehek EA (2002). Effects of catecholamine uptake blockers in the caudate-putamen and subregions of the medial prefrontal cortex of the rat. Brain Research 936, 58-67. (Pubitemid 34461933)
63. Meltzer HY, McGurk SR (1999). The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin 25, 233-255. (Pubitemid 29272503)
64. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, et al. (2000). Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. European Journal of Neuroscience 12, 1079-1095. (Pubitemid 30168787)
65. Miner LH, Schroeter S, Blakely RD, Sesack SR (2003). Ultrastructural localization of the norepinephrine transporter in superficial and deep layers of the rat prelimbic prefrontal cortex and its spatial relationship to probable dopamine terminals. Journal of Comparative Neurology 466, 478-494. (Pubitemid 37305993)
66. Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic Coordinates. Sydney: Academic.
67. Pozzi L, Invernizzi R, Cervo L, Vallebuona F, et al. (1994). Evidence that extracellular concentrations of dopamine are regulated by noradrenergic neurons in the frontal cortex of rats. Journal of Neurochemistry 63, 195-200. (Pubitemid 24184918)
68. Raiteri M, del Carmine R, Bertollini A, Levi G (1977). Effect of sympathomimetic amines on the synaptosomal transport of noradrenaline, dopamine and 5-hydroxytryptamine. European Journal of Pharmacology 41, 133-143. (Pubitemid 8015308)
69. Robbins TW, Roberts AC (2007). Differential regulation of fronto-executive function by the monoamines and acetylcholine. Cerebral Cortex 17, i151-i160.
70. Robbins TW, Arnsten AF (2009). The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annual Review of Neuroscience 32, 267-287.
71. Robinson TE, Mocsary Z, Camp DM, Whishaw IQ (1994). Time course of recovery of extracellular dopamine following partial damage to the nigrostriatal dopamine system. Journal of Neuroscience 14, 2687-2696. (Pubitemid 24140895)
72. Robinson TE, Whishaw IQ (1988). Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats. Brain Research 450, 209-224.
73. Rollema H, Lu Y, Schmidt AW, Zorn SH (1997). Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. European Journal of Pharmacology 338, R3-R5. (Pubitemid 27507749)
74. Romero L, Artigas F (1997). Preferential potentiation of the effects of serotonin uptake inhibitors by 5-HT1A receptor antagonists in the dorsal raphe pathway: role of somatodendritic autoreceptors. Journal of Neurochemistry 68, 2593-2603. (Pubitemid 27218184)
75. Romero L, Jernej B, Bel N, Cicin-Sain L, et al. (1998). Basal and stimulated extracellular serotonin concentration in the brain of rats with altered serotonin uptake. Synapse 28, 313-321. (Pubitemid 28113515)
76. Sara SJ (2009). The locus coeruleus and noradrenergic modulation of cognition. Nature Reviews Neuroscience 10, 211-223.
77. Schroeter S, Apparsundaram S, Wiley RG, Miner LH, et al. (2000). Immunolocalization of the cocaine- and antidepressant-sensitive l-norepinephrine transporter. Journal of Comparative Neurology 420, 211-232. (Pubitemid 30185979)
78. Seeman P, Lee T (1975). Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188, 1217-1219.
79. Seguela P, Watkins KC, Geffard M, Descarries L (1990). Noradrenaline axon terminals in adult rat neocortex: an immunocytochemical analysis in serial thin sections. Neuroscience 35, 249-264. (Pubitemid 20176738)
80. Sesack SR, Hawrylak VA, Matus C, Guido MA, et al. (1998). Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. Journal of Neuroscience 18, 2697-2708. (Pubitemid 28141815)
81. Schotte A, Janssen PF, Megens AA, Leysen JE (1993). Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Research 631, 191-202. (Pubitemid 24009988)
82. Svensson TH (2003). Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Progress in Neuro-Psychopharmacology & Biological Psychiatry 27, 1145-1158. (Pubitemid 37464959)
83. Swanson CJ, Perry KW, Koch-Krueger S, Katner J, et al. (2006). Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology 50, 755-760.
84. Szot P, Miguelez C, White SS, Franklin A, et al. (2010). A comprehensive analysis of the effect of DSP4 on the locus coeruleus noradrenergic system in the rat. Neuroscience 166, 279-291.
85. Tanda G, Carboni E, Frau R, Di Chiara G (1994). Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology (Berlin) 115, 285-288. (Pubitemid 24207795)
86. Tseng KY, Kargieman L, Gacio S, Riquelme LA, et al. (2005). Consequences of partial and severe dopaminergic lesion on basal ganglia oscillatory activity and akinesia. European Journal of Neuroscience 22, 2579-2586. (Pubitemid 41759000)
87. Valentini V, Frau R, Di Chiara G (2004). Noradrenaline transporter blockers raise extracellular dopamine in medial prefrontal but not parietal and occipital cortex: differences with mianserin and clozapine. Journal of Neurochemistry 88, 917-927. (Pubitemid 38199313)
88. Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, et al. (2007). Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nature Neuroscience 10, 376-384.
89. Vos PE, Steinbusch HW, Ronken E, van Ree JM (1999). Short and long term plasticity after lesioning of the cell body or terminal field area of the dopaminergic mesocorticolimbic system in the rat. Brain Research 831, 237-247. (Pubitemid 29336206)
90. Wadenberg ML, Wiker C, Svensson TH (2007). Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: experimental evidence. International Journal of Neuropsychopharmacology 10, 191-202.
91. Weinberger DR, Berman KF, Chase TN (1988). Mesocortical dopaminergic function and human cognition. Annals of the New York Academy of Sciences 537, 330-338. (Pubitemid 19029555)
92. Westerink BH, Kawahara Y, De Boer P, Geels C, et al. (2001). Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. European Journal of Pharmacology 412, 127-138. (Pubitemid 32124859)
93. Williams GV, Goldman-Rakic PS (1995). Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376, 572-575.
94. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, et al. (1990). Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends in Neuroscience 13, 290-296. (Pubitemid 20193461)